Berman David M 4

4 · Immunocore Holdings plc · Filed Dec 8, 2025

Form 4

Period: 2025-12-04

HEAD OF R&D

Transactions

Exercise/Conversion
Ordinary Shares
2025-12-04$17.46/sh+31,341$547,214→ 31,341 total
Sale
Ordinary Shares
2025-12-04$40.26/sh−31,341$1,261,789→ 0 total
Exercise/Conversion
Ordinary Shares
2025-12-05$17.46/sh+572$9,987→ 572 total
Sale
Ordinary Shares
2025-12-05$40.14/sh−572$22,960→ 0 total
Exercise/Conversion
Employee Share Option (Right to Buy)
2025-12-04−31,341→ 12,404 total
Exercise: $17.46Exp: 2028-09-12→ Ordinary Shares (31,341 underlying)
Exercise/Conversion
Employee Share Option (Right to Buy)
2025-12-05−572→ 11,832 total
Exercise: $17.46Exp: 2028-09-12→ Ordinary Shares (572 underlying)

Footnotes (4)

[F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.44 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]Immediately exercisable.

Documents

1 file